ArticleCancers2019
FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Metabolic Reprogramming-Related Genes in Lung Adenocarcinoma: Identification and Prognostic Model Construction.World journal of oncology · 2025Article
- Single-Cell Transcriptomic Profiling Reveals KRAS/TP53-Driven Neutrophil Reprogramming in Luad: A Multi-Gene Prognostic Model and Therapeutic Targeting of RHOV.Oncology research · 2025Article
- Family with sequence similarity 83, member A (FAM83A) inhibits ferroptosis via the Wnt/β-catenin pathway in lung squamous cell cancer.Cell death discovery · 2024Article
- Diagnostic value of immune-related biomarker FAM83A in differentiating malignant from benign pleural effusion in lung adenocarcinoma.Discover oncology · 2024Article
- FAM83B regulates mitochondrial metabolism and anti-apoptotic activity in pulmonary adenocarcinoma.Apoptosis : an international journal on programmed cell death · 2024Article
- Integrated whole-exome and bulk transcriptome sequencing delineates the dynamic evolution from preneoplasia to invasive lung adenocarcinoma featured with ground-glass nodules.Cancer medicine · 2024Article
- Integrated analysis reveals critical cisplatin-resistance regulators E2F7 contributed to tumor progression and metastasis in lung adenocarcinoma.Cancer cell international · 2024Article
- Article
- Fatty acid metabolism prognostic signature predicts tumor immune microenvironment and immunotherapy, and identifies tumorigenic role of MOGAT2 in lung adenocarcinoma.Frontiers in immunology · 2024Article
- Non-small Cell Lung Cancer Epigenomes Exhibit Altered DNA Methylation in Smokers and Never-smokers.Genomics, proteomics & bioinformatics · 2023Article
- Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia.Scientific reports · 2023Article
- FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway.BMC pulmonary medicine · 2023Article
- Involvement of FAM83 Family Proteins in the Development of Solid Tumors: An Update Review.Journal of Cancer · 2023Review
- Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.Biology · 2022Article
- Establishing an 8-gene immune prognostic model based on TP53 status for lung adenocarcinoma.Journal of clinical laboratory analysis · 2022Article
- Comprehensive analysis of the expression, prognostic significance, and function of FAM83 family members in breast cancer.World journal of surgical oncology · 2022Article
- FAM83B is involved in thyroid cancer cell differentiation and migration.Scientific reports · 2022Article
- FAM83A is a potential biomarker for breast cancer initiation.Biomarker research · 2022Article
- Aberrant epigenetic and transcriptional events associated with breast cancer risk.Clinical epigenetics · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Although targeted therapy has improved the survival rates in the last decade, non-small-cell lung cancer (NSCLC) is still the most common cause of cancer-related death. The challenge of identifying new targets for further effective therapies still remains. The FAMily with sequence similarity 83 (FAM83) members have recently been described as novel oncogenes in numerous human cancer specimens and shown to be involved in epidermal growth factor receptor (EGFR) signaling. Here, gene expression of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.